{
    "pmid": "41455776",
    "title": "Atorvastatin suppresses high-risk colorectal adenomas via reprogramming of lipid metabolism and Inhibition of stemness.",
    "abstract": "As critical precursors to colorectal cancer (CRC), high-risk colorectal adenomas (HR-CRAs) lack effective chemopreventive strategies beyond endoscopic resection. We previously established a standardized protocol for culturing patient-derived HR-CRA organoids (HR-CRA-PDOs), creating a robust platform for targeted drug discovery in colorectal premalignancy. Bioinformatics investigation was conducted to unveil the significant dysregulation of lipid metabolism in HR-CRAs. HR-CRA-PDOs were primarily cultured and exposed to gradient concentrations of atorvastatin, with drug responses evaluated with high-throughput and high-content imaging and ATP-based viability assays. Parallel in vivo validation utilized AOM/DSS-induced mouse model under either normal or high-fat diets. Histological and molecular analyses were conducted to evaluate adenoma dynamics, apoptosis, and lipid metabolism-related gene and protein expressions. Bioinformatics analysis of GEO database (GSE100179 and GSE161277) revealed that HR-CRAs are characterized by dysregulated lipid metabolism, particularly through the upregulation of fatty acid metabolism pathways. In vitro, atorvastatin significantly inhibited HR-CRA-PDO growth in a dose-dependent manner via apoptosis induction and proliferation arrest. Mechanistically, atorvastatin treatment led to significant alterations of gene expression in lipid metabolism pathways including ACOX1, ACOX2, FABP2, NRG1, PPAR-Î± and SREBF1, concomitant with stemness marker suppression in HR-CRA-PDOs. In vivo, atorvastatin markedly reduced CRA burden in AOM-DSS-induced mouse model, particularly demonstrating enhanced efficacy in high-fat diet contexts. This translational study establishes atorvastatin's dual mechanism in metabolic reprogramming and stemness inhibition, suggesting its potential as a therapeutic strategy for CRA prevention and treatment.",
    "disease": "colorectal cancer",
    "clean_text": "atorvastatin suppresses high risk colorectal adenomas via reprogramming of lipid metabolism and inhibition of stemness as critical precursors to colorectal cancer crc high risk colorectal adenomas hr cras lack effective chemopreventive strategies beyond endoscopic resection we previously established a standardized protocol for culturing patient derived hr cra organoids hr cra pdos creating a robust platform for targeted drug discovery in colorectal premalignancy bioinformatics investigation was conducted to unveil the significant dysregulation of lipid metabolism in hr cras hr cra pdos were primarily cultured and exposed to gradient concentrations of atorvastatin with drug responses evaluated with high throughput and high content imaging and atp based viability assays parallel in vivo validation utilized aom dss induced mouse model under either normal or high fat diets histological and molecular analyses were conducted to evaluate adenoma dynamics apoptosis and lipid metabolism related gene and protein expressions bioinformatics analysis of geo database gse and gse revealed that hr cras are characterized by dysregulated lipid metabolism particularly through the upregulation of fatty acid metabolism pathways in vitro atorvastatin significantly inhibited hr cra pdo growth in a dose dependent manner via apoptosis induction and proliferation arrest mechanistically atorvastatin treatment led to significant alterations of gene expression in lipid metabolism pathways including acox acox fabp nrg ppar and srebf concomitant with stemness marker suppression in hr cra pdos in vivo atorvastatin markedly reduced cra burden in aom dss induced mouse model particularly demonstrating enhanced efficacy in high fat diet contexts this translational study establishes atorvastatin s dual mechanism in metabolic reprogramming and stemness inhibition suggesting its potential as a therapeutic strategy for cra prevention and treatment"
}